Skip to content
value.today

US Genomics Inc.

Total raised
$18 M
4 rounds on record
Latest round
$4 M
Oct 2013
First round on record
Dec 2009
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of US Genomics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2013$4 MNo. 4$2 to $10 million

US Genomics Inc.: Raise no. 4, Oct 2013

Investors in this round

5 investors had bought by the notice of Oct 15, 2013: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $9 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ann Merrifield · Executive Officer, Director
  • Frederick Blume · Director
  • Gus Lawlor · Director
  • Steve Gullans · Director
  • Tara Butler · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Offering Amount and Total Amount Sold includes value of promissory notes converted into equity ($542,181).”

Signed by Ann Merrifield, President. Source: SEC Form D, newest notice filed Oct 15, 2013. Read the notice at the SEC.

equitySEC
Jul 2011$12 MNo. 3$10 to $50 million

US Genomics Inc.: Raise no. 3, Jul 2011

Investors in this round

5 investors had bought by the notice of Nov 4, 2011: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David J. Hoey · Executive Officer, Director
  • John J. Canepa · Executive Officer, Director
  • Augustine J. Lawlor · Director
  • Enrico J. Petrillo · Director
  • Stephen J. Gullans · Director
  • Tara J. Butler · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John J. Canepa, President and chief executive officer. Source: SEC Form D and 1 amendment, newest notice filed Nov 4, 2011. Read the notice at the SEC.

equitySEC
Oct 2010$2 MNo. 2Under $2 million

US Genomics Inc.: Raise no. 2, Oct 2010

Investors in this round

5 investors had bought by the notice of Dec 13, 2010: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John J. Canepa · Executive Officer, Director
  • Augustine J. Lawlor · Director
  • David J. Hoey · Director
  • Enrico J. Petrillo · Director
  • Stephen J. Gullans · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John J. Canepa, President and chief executive officer. Source: SEC Form D and 1 amendment, newest notice filed Dec 13, 2010. Read the notice at the SEC.

equitySEC
Dec 2009$1 MNo. 1Under $2 million

US Genomics Inc.: Raise no. 1, Dec 2009

Investors in this round

8 investors had bought by the notice of Jan 19, 2010: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $2 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David J. Hoey · Executive Officer, Director
  • John J. Canepa · Executive Officer, Director
  • John J. Harris · Executive Officer
  • Rudolf J. Gilmanshin · Executive Officer
  • Augustine J. Lawlor · Director
  • Enrico J. Petrillo · Director
  • James J. Saalfield · Director
  • Salvatore J. Salamone · Director
  • Stephen J. Knight · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John J. Canepa, President and chief executive officer. Source: SEC Form D, newest notice filed Jan 19, 2010. Read the notice at the SEC.

equity, debtSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • US Genomics Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2013).

    SEC Form D · Oct 2013

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2013

That is all the official record says: US Genomics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of US Genomics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 8 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by US Genomics Inc.
NameRoleNamed in
Ann MerrifieldExecutive officerOct 2013
David J. HoeyExecutive officerNov 2011
John J. CanepaExecutive officerNov 2011
John J. HarrisExecutive officerJan 2010
Rudolf J. GilmanshinExecutive officerJan 2010
Ann MerrifieldDirectorOct 2013
Frederick BlumeDirectorOct 2013
Gus LawlorDirectorOct 2013
Steve GullansDirectorOct 2013
Tara ButlerDirectorOct 2013
Augustine J. LawlorDirectorNov 2011
David J. HoeyDirectorNov 2011
Enrico J. PetrilloDirectorNov 2011
John J. CanepaDirectorNov 2011
Stephen J. GullansDirectorNov 2011
Tara J. ButlerDirectorNov 2011
James J. SaalfieldDirectorJan 2010
Salvatore J. SalamoneDirectorJan 2010
Stephen J. KnightDirectorJan 2010